Avoidance of systemic anticoagulation during intermittent haemodialysis with heparin-grafted polyacrilonitrile membrane and citrate-enriched dialysate: a retrospective cohort study

BMC Nephrology

Christian Tielemans¹  Kristine Jacobs¹  Dries Boone¹  Rita Jacobs²  Karl Martin Wissing¹  Karlien François¹ 

[1] Department of Nephrology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Jette, Belgium;Department of Intensive Care, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Jette, Belgium

关键词: Coagulation;    Heparin-grafted dialyzer;    Citrate dialysate;    Anticoagulation-free haemodialysis;   

Others  :  848350
DOI  :  10.1186/1471-2369-15-104

 received in 2014-03-03, accepted in 2014-06-26,  发布年份 2014

【 摘 要 】

Background

Since October 2010, the combination of a heparin-grafted polyacrilonitrile (AN69ST) membrane with a 0.80 mmol/L citric acid-containing dialysate is routinely used in our centre for intermittent haemodialysis, without systemic anticoagulation, in critically ill patients with increased bleeding risk. The primary outcome of this retrospective cohort study was to assess the development of circuit clotting during these dialysis procedures. Secondly, we assessed the impact of clotting on treatment duration, the incidence rate of coagulation-induced retransfusion failure and the association of patient and dialysis characteristics with the occurrence of clotting.

Methods

Dialysis and patient data on consecutive intermittent haemodialysis procedures, performed at the Intensive Care Unit of Universitair Ziekenhuis Brussel between October 2010 and March 2012, were retrospectively reviewed. We used descriptive statistics as well as a random effects logit model with patient identity as a panel variable to assess associations.

Results

Of a total of 309 treatments combining a heparin-grafted AN69ST membrane and a 0.8 mmol/L citric acid-enriched dialysate in 94 patients, circuit clotting was reported in 17.5% (95% CI 13.2% to 21.7%; N = 54), and in 19% (95% CI 13.6% to 24.4%; N = 40) of sessions with prescribed treatment time ≥ 4 hours (N = 210). Clotting shortened treatment time in 15.2% (95% CI 11.4% to 19.7%; N = 47) of sessions by a median of 55 (IQR 20 to 80) minutes. Complete clotting of the circuit with inability for retransfusion occurred in 4.2% (95% CI 2.2% to 7.0%; N = 13) of sessions. Circuit coagulation was not associated with APACHE II score, patient age, gender, number of treatments, type of vascular access or ultrafiltration rate.

Conclusion

Intermittent haemodialysis without systemic anticoagulation combining a heparin-grafted AN69ST dialyzer with a citrate-enriched dialysate favourably compares as to clotting complications with the published outcomes of anticoagulation-free intermittent haemodialysis strategies using saline flushes, heparin-coated dialyzer in combination with regular dialysate or regional citrate anticoagulation with calcium supplemented dialysate. The incidence of circuit clotting in our cohort appears to be higher than previously reported for regional citrate anticoagulation with a calcium-free dialysate.

【 授权许可】

   
2014 François et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]European Best Practice Guidelines Expert Group on Hemodialysis ERA: Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant 2002, 17(Suppl 7):63-71.
• [2]Casati S, Moia M, Graziani G, Cantaluppi A, Citterio A, Mannucci PM, Ponticelli C: Hemodialysis without anticoagulants: efficiency and hemostatic aspects. Clin Nephrol 1984, 21(2):102-105.
• [3]Sanders PW, Taylor H, Curtis JJ: Hemodialysis without anticoagulation. Am J Kidney Dis 1985, 5(1):32-35.
• [4]Caruana RJ, Raja RM, Bush JV, Kramer MS, Goldstein SJ: Heparin free dialysis: comparative data and results in high risk patients. Kidney Int 1987, 31(6):1351-1355.
• [5]Schwab SJ, Onorato JJ, Sharar LR, Dennis PA: Hemodialysis without anticoagulation. One-year prospective trial in hospitalized patients at risk for bleeding. Am J Med 1987, 83(3):405-410.
• [6]Stamatiadis DN, Helioti H, Mansour M, Pappas M, Bokos JG, Stathakis CP: Hemodialysis for patients bleeding or at risk for bleeding, can be simple, safe and efficient. Clin Nephrol 2004, 62(1):29-34.
• [7]Maurice L, Marc D, Joan F, Renaud F, Frederique M, Nathalie L, Patrick R: A randomized controlled multicenter trial of a heparin-grafted polyacrylonitrile membrane for no-heparin hemodialysis versus standard-of-care: results of the HepZero Study. Late-breaking clinical trial posters ISN World Congress of Nephrology 2013 SA-PO1084. Clin J Am Soc Nephrol 2013, 24:4B.
• [8]Schneider M, Thomas K, Liefeldt L, Kindgen-Milles D, Peters H, Neumayer HH, Morgera S: Efficacy and safety of intermittent hemodialysis using citrate as anticoagulant: a prospective study. Clin Nephrol 2007, 68(5):302-307.
• [9]Kreuzer M, Bonzel KE, Buscher R, Offner G, Ehrich JH, Pape L: Regional citrate anticoagulation is safe in intermittent high-flux haemodialysis treatment of children and adolescents with an increased risk of bleeding. Nephrol Dial Transplant 2010, 25(10):3337-3342.
• [10]Apsner R, Buchmayer H, Gruber D, Sunder-Plassmann G: Citrate for long-term hemodialysis: prospective study of 1,009 consecutive high-flux treatments in 59 patients. Am J Kidney Dis 2005, 45(3):557-564.
• [11]Gubensek J, Kovac J, Benedik M, Marn-Pernat A, Knap B, Ponikvar R, Buturovic-Ponikvar J: Long-term citrate anticoagulation in chronic hemodialysis patients. Ther Apher Dial 2011, 15(3):278-282.
• [12]Ahmad S, Callan R, Cole JJ, Blagg CR: Dialysate made from dry chemicals using citric acid increases dialysis dose. Am J Kidney Dis 2000, 35(3):493-499.
• [13]Kossmann RJ, Gonzales A, Callan R, Ahmad S: Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study. Clin J Am Soc Nephrol 2009, 4(9):1459-1464.
• [14]Chanard J, Lavaud S, Maheut H, Kazes I, Vitry F, Rieu P: The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane. Nephrol Dial Transplant 2008, 23(6):2003-2009.
• [15]Sands JJ, Kotanko P, Segal JH, Ho CH, Usvat L, Young A, Carter M, Sergeyeva O, Korth L, Maunsell E, Zhu Y, Krishnan M, Diaz-Buxo JA: Effects of citrate acid concentrate (citrasate(R)) on heparin N requirements and hemodialysis adequacy: a multicenter, prospective noninferiority trial. Blood Purif 2012, 33(1–3):199-204.
• [16]Evenepoel P, Dejagere T, Verhamme P, Claes K, Kuypers D, Bammens B, Vanrenterghem Y: Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis 2007, 49(5):642-649.
• [17]Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C: Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005, 294(7):813-818.
• [18]Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA: RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006, 10(3):R73. BioMed Central Full Text
• [19]Goldberg R, Dennen P: Long-term outcomes of acute kidney injury. Adv Chronic Kidney Dis 2008, 15(3):297-307.
• [20]Lines SW, Cherukuri A, Murdoch SD, Bellamy MC, Lewington AJ: The outcomes of critically ill patients with acute kidney injury receiving renal replacement therapy. Int J Artif Organs 2011, 34(1):2-9.
• [21]Lazarus JM: Complications in hemodialysis: an overview. Kidney Int 1980, 18(6):783-796.
• [22]Janssen MJ, van der Meulen J: The bleeding risk in chronic haemodialysis: preventive strategies in high-risk patients. Neth J Med 1996, 48(5):198-207.
• [23]Franchini M, Veneri D, Lippi G: Inflammation and hemostasis: a bidirectional interaction. Clin Lab 2007, 53(1–2):63-67.
• [24]Chanard J, Lavaud S, Paris B, Toure F, Rieu P, Renaux JL, Thomas M: Assessment of heparin binding to the AN69 ST hemodialysis membrane: I. Preclinical studies. ASAIO J 2005, 51(4):342-347.
• [25]Lohr JW, Schwab SJ: Minimizing hemorrhagic complications in dialysis patients. J Am Soc Nephrol 1991, 2(5):961-975.